Applying Novel Treatment Plans to Improve the Overall Quality of Life in Patients With Moderate-to-Severe Idiopathic Pulmonary Fibrosis

Program Dates: October 12, 2017 to October 11, 2018
Credits: 1.00 AMA PRA Category 1 Credit(s)™

Schematic illustration of human lungs with the different elements on a colored background. Collage.

Applying Novel Treatment Plans to Improve the Overall Quality of Life in Patients With Moderate-to-Severe Idiopathic Pulmonary Fibrosis

Program Overview

This CME program is derived from content presented at the Eastern Pulmonary Conference in Palm Beach, Florida. The inter professional, expert faculty, which consists of a pulmonologist, a radiologist and a pathologist, will highlight recent scientific advances in the treatment and management of patients with moderate-to-severe idiopathic pulmonary fibrosis (IPF). The faculty will outline interactive clinical cases that encompass the various disciplines of the healthcare team involved in care of the IPF patient population. Optimal methods for educating newly diagnosed patients and addressing barriers that may affect outcomes will be addressed. At the conclusion of this discussion-based activity, learners will be better acquainted with optimal treatment, monitoring and management techniques for patients with IPF.

Target Audience

Pulmonologists, primary care physicians, and other healthcare clinicians responsible for the care of patients with idiopathic pulmonary fibrosis (IPF).

Learning Objectives

  1. Identify the pathophysiology of IPF, including risk factors, comorbidities, and disease progression
  2. Analyze the clinical trial data for novel therapeutics for the treatment of IPF
  3. Apply optimal strategies and guideline recommendations to create more effective treatment plans for patients with IPF.


Screen Shot 2017-09-26 at 11.43.15 AMMarilyn K. Glassberg Csete, MD
Professor of Medicine, Surgery, and Pediatrics
Director, Interstitial and Rare Lung Disease Program
University of Miami Miller School of Medicine
Miami, Florida



Screen Shot 2017-09-26 at 11.45.02 AMMary Beth Beasley, MD
Professor of Pathology
Mount Sinai Medical Center
New York, New York




Screen Shot 2017-09-26 at 11.46.49 AMMary M. Salvatore, MD, MBA
Assistant Professor of Radiology
Mount Sinai Health System
Thoracic Radiologist
The Mount Sinai Hospital
New York, New York



Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:
 Marilyn K. Glassberg Csete, MDConsultant/Advisor: Bellerophon Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; Mesoblast Ltd; Patara PharmaGrant/Research Support: Genentech, Inc.
Mary Beth Beasley, MDConsultant/Advisor: Genentech, Inc.; Merck & Co.
Mary M. Salvatore, MD, MBA Speaker’s Bureau: Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Genentech, Inc.

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Emma Boring and Nicole Brestowski hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Biogen do not recommend the use of any agent outside of the labeled indications.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact [email protected]


Provided by AcademicCME-web